2.28
Schlusskurs vom Vortag:
$2.28
Offen:
$2.34
24-Stunden-Volumen:
33,551
Relative Volume:
0.19
Marktkapitalisierung:
$3.91M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-4.84M
KGV:
-0.3058
EPS:
-7.4566
Netto-Cashflow:
$-3.84M
1W Leistung:
-8.80%
1M Leistung:
-38.96%
6M Leistung:
-55.36%
1J Leistung:
-76.56%
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs PSNYW, GOODO, SHMD, CHAD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.29 | 773.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.35 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.31 | 220.96M | 52.15M | -21.46M | 0 | -0.4675 |
|
CHAD
Direxion Daily CSI 300 China A
|
7.8954 | 197.39M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.62 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development - Quiver Quantitative
A nasal PTSD treatment met specs for nine months - Stock Titan
Silo Pharma Stock Price Forecast. Should You Buy SILO? - StockInvest.us
Silo Pharma Inc (NYSE: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - Kalkine
Silo Pharma Inc (NASDAQ: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - Kalkine
Silo Pharma Inc (SILO) Peer Comparison – Compare with Others - Value Research
Silo Pharma Inc (SILO) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Silo Pharma Acquires Digital Assets via Stock Issuance - The Globe and Mail
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com South Africa
Form 8K Silo Pharma Inc For: 19 August - Investing.com India
Silo Pharma Acquires Software and IP From Parkview Consulting for 165,000 Shares - TradingView
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting - TradingView
Silo Pharma Secures Canadian Patent Allowance for PTSD Treatment SPC-15 - citybuzz -
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com Canada
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - The Manila Times
Silo Pharma Receives Notice of Allowance for Canadian Patent Application Covering Lead Asset Spc-15 Targeting Ptsd and Other Stress-Induced Psychiatric Disorders - marketscreener.com
Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current UpdateSuperTrend - Vinanet
Silo Pharma Shareholders Approve Major Share Authorization Expansion - TipRanks
Silo Pharma (SILO) holders approve lifting share cap from 6.7M - Stock Titan
Silo Pharma (SILO) Slips 0.62% to $3.20 as Shares Consolidate Between Key Technical LevelsStock Picks - Vinanet
Silo Pharma (SILO) trims cash burn, mitigates going-concern risk in Q2 2026 - Stock Titan
Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Silo Pharma (SILO) investor group discloses 9.99% warrant-based ownership cap - Stock Titan
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026. - marketscreener.com
Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Granted European Patent Covering Novel PTSD Therapy - The Manila Times
Silo Pharma receives European patent for SPC-15 PTSD treatment - Investing.com India
Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy - Quiver Quantitative
SILO Q4 2023 Earnings: Wider-than-Expected Loss of -$5.40 per Share Highlights Heavy Pre-Revenue InvestmentTax Rate Impact - vinanet.vn
Silo Pharma Inc (SILO) Stock News Today - TradingKey
Silo Pharma Inc (SILO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Silo Pharma, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Silo Pharma (SILO) Q4 2023 Earnings: Wider-Than-Expected Loss Sends Shares Down 20%Quarterly Earnings - vinanet.vn
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - marketscreener.com
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon - GlobeNewswire
SILO|Silo Pharma Inc|Price:3.200|Chg%:-0.020 - TradingKey
SILO Q4 2023 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage R&D SpendingQuarterly Earnings Report - vinanet.vn
Silo Pharma, Inc. Revenue Breakdown – NASDAQ:SILO - TradingView
Silo Pharma Inc (SILO) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Silo Pharma Inc. Q4 2023 Earnings: Wider-Than-Expected Loss Weighs on SharesHigh Estimate Range - vinanet.vn
Silo Pharma Inc (SILO) Income Statement - TradingKey
SILO|Silo Pharma Inc|Price:4.470|Chg%:+0.010 - TradingKey
Silo Pharma Inc (SILO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Silo Pharma Inc (SILO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Form S-3 Silo Pharma Inc For: 24 July By Investing.com - Investing.com India
Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common StockSEC Filing - TradingView
SILO Q4 2023 Earnings: Significant EPS Miss Highlights Operational ChallengesEarnings Volatility Report - vinanet.vn
Silo Pharma Advances AI Agent Platform Toward Commercial Launch And Progresses Lead PTSD Drug Program SPC-15 - marketscreener.com
Silo Pharma plans AI platform launch, advances PTSD drug program By Investing.com - Investing.com Canada
Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development - Quiver Quantitative
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Silo Pharma Inc-Aktie (SILO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):